drugset
drugset / Trial / NCT04693195

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195 ↗

Phase 2 Completed 142 enrolled Bellus Health Inc. - a GSK company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD).

Timeline

Start
2020-12-09
Primary completion
2021-10-04
Completion
2021-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Camlipixant Small molecule — Oral

Indications

atopic eczema